ESSA Pharma (US:EPIX) Prnewswireยท2025-01-31 10:45Core Viewpoint - A class action securities lawsuit has been filed against ESSA Pharma Inc. alleging securities fraud that affected investors between December 12, 2023, and October 31, 2024 [1][2]. Group 1: Lawsuit Details - The complaint claims that ESSA Pharma Inc. made false statements regarding the efficacy of masofaniten in combination with enzalutamide for treating prostate cancer, suggesting it had no clear benefit over enzalutamide alone [2]. - It is alleged that the M-E Combination Study was unlikely to meet its prespecified Phase 2 primary endpoint, contradicting the company's public statements about masofaniten's prospects [2]. - The lawsuit asserts that the defendants overstated masofaniten's clinical, regulatory, and commercial prospects, leading to materially false and misleading public statements [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until March 25, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4]. - The firm has over 70 employees dedicated to serving clients in complex securities litigation, highlighting its extensive expertise in this area [4].